2007
DOI: 10.1200/jco.2007.25.18_suppl.14065
|View full text |Cite
|
Sign up to set email alerts
|

Effect of sorafenib in symptomatic metastatic medullary thyroid cancer

Abstract: 14065 Background: RET receptor tyrosin kinase activity plays a major role in medullary thyroid cancer (MTC) tumor growth. Sorafenib is an oral agent that selectively targets RET tyrosine kinases. Methods: 5 patients (pts) with metastatic MTC with excessive elevation of calcitonin(CTN) serum levels entered this pilotstudy. Hypercalcitonemia-related symptoms were present in all pts (3 severe diarrhea, 2 moderate) and metastasis- related symptoms were present in 4 pts (2 severe pain, 2 moderate). All pts had had… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
11
0
3

Year Published

2009
2009
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 49 publications
(15 citation statements)
references
References 0 publications
1
11
0
3
Order By: Relevance
“…However, neither the timing nor the degree of tumour marker response signifi cantly correlated with the degree or duration of RECIST response. Overall, our results with sorafenib in patients with MTC are in good agreement with the results of small studies done by others [9,10] The positive results in our study are even superior to a just published report of a 6.3 % rate of PR in sporadic MTC [11] , one reason may be selection of patients with clearly demonstrated marked progressive disease pre-therapeutically in our study.…”
Section: Discussion ▼supporting
confidence: 92%
See 1 more Smart Citation
“…However, neither the timing nor the degree of tumour marker response signifi cantly correlated with the degree or duration of RECIST response. Overall, our results with sorafenib in patients with MTC are in good agreement with the results of small studies done by others [9,10] The positive results in our study are even superior to a just published report of a 6.3 % rate of PR in sporadic MTC [11] , one reason may be selection of patients with clearly demonstrated marked progressive disease pre-therapeutically in our study.…”
Section: Discussion ▼supporting
confidence: 92%
“…In a phase II trial of sorafenib in patients with metastatic papillary thyroid cancer, 15 % of the patients showed a partial response, and 56 % had stable disease longer than 6 months [8] . Clinical observations using sorafenib in small patient groups with MTC showed partial response in 2 of 5 and in 3 of 6 patients, respectively [9,10] . In a recent phase II trial of sorafenib in metastatic medullary thyroid cancer, 1 of 16 patients (6.3 % ) achieved partial response, 14 had stable disease [11] Not all patients qualify for the ongoing studies using small molecules like vandetanib or XL 184, or they develop progressive disease and / or refuse to participate in a placebo-controlled study without the possibility of crossing over.…”
Section: Discussionmentioning
confidence: 98%
“…Recently, a number of promising agents have been studied in phase I and phase II clinical trials with results presented at national scientific meetings (320)(321)(322)(323)(324). Several of these agents have demonstrated significant partial response rates in the range of 20-50% with a larger number of patients demonstrating stable disease.…”
Section: And Recommendation 108mentioning
confidence: 99%
“…apresentado como única opção no momento e amparado por estudos utilizando soF no cMt, a paciente o usou por 24 meses (800 mg/dia por 8 meses e 400 mg por 16 meses). corroborando esses resultados, outros estudos relataram a necessidade de reduzir a dose ao longo do tratamento por conta dos efeitos colaterais 7 , e o tempo médio de uso da medicação é de 15 meses 8 .…”
Section: Relato De Casounclassified